MSD’s Keytruda sprints towards label expansion in endometrial cancer
20 Feb 2024
Phase 3Clinical ResultDrug ApprovalPriority ReviewImmunotherapy
Preview
Source: Pharmaceutical Technology
Keytruda is already approved in combination with Lenvima (lenvatinib) to treat endometrial carcinoma that is not MSI-H or dMMR. Credits: Michael Vi/Shutterstock.com
The United States Food and Drug Administration (FDA) has granted priority review for a new supplemental Biologics License Application (sBLA) for a combination treatment with Merck & Co’s (MSD) Keytruda (pembrolizumab) and chemotherapy for advanced or recurrent endometrial carcinoma.
Keytruda is already approved in combination with Eisai’s Lenvima (lenvatinib) for the treatment of advanced endometrial carcinoma that is not microsatellite-high (MSI-H) or deficient mismatch repair (dMMR). With the latest priority review, it could be indicated as a combination treatment with chemotherapy that is followed by a single-agent Keytruda in this indication. As per the press release, the treatment has a Prescription Drug User Fee Act (PDUFA) of 21 June 2024.
The priority review was granted based on results from a National Cancer Institute (NCI)Cancer Institute (NCI)-sponsored Phase III (NCT03914612) study, dubbed NRG-GY018, a randomised, placebo-controlled clinical trial evaluating the efficacy of adding Keytruda to standard of care chemotherapy for stage III-IV or recurrent endometrial cancerstage III-IV or recurrent endometrial cancer.
Compared to standard of care chemotherapy alone, the study reported that the addition of Keytruda was demonstrated to decrease the risk of disease progression or death by 46% in patients with mismatch repair proficient (pMMR) cancer and 70% in patients with dMMR endometrial cancer, as shared at the 2023 Society of Gynecologic Oncology (SGO) on Women’s Cancer meeting.
The study used progression-free survival (PFS) as its primary outcome measure and employed various secondary outcome measures which included safety, overall survival, and health-related quality of life. As per the press release, the study showed “statistically significant and clinically meaningful improvement” in PFS.
See Also:LAE-001 by Laekna Therapeutics Shanghai for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
TG-01 by Circio Holding for Non-Small Cell Lung Cancer: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
“If approved, KEYTRUDA would be the first immunotherapy indicated for the frontline treatment of advanced endometrial cancer regardless of mismatch repair status,” said Dr. Gursel Aktan, vice president, global clinical development at Merck Research Laboratories in the 20 February press release.
Merck & Co has started the year off strong following a 12 January label expansion for Keytruda to treat certain types of advanced cervical cancer in combination with chemoradiotherapy. The expansion marked the third FDA approval for Keytruda in cervical cancer.
GlobalData estimates Keytruda to bring in over $33bn in 2028.
GlobalData is the parent company of Pharmaceutical Technology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.